QuarterHawk — Equity ResearchQuarterHawk — Equity Research

USANA Health Sciences, Inc. (USNA)

Consumer Defensive

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore 2 is below the required floor of 3 (shadow branch not eligible) and 20-day average dollar volume of about $2.79M is below the $5M liquidity floor; no breakout stop qualifies (no base, price under every major MA and at the low end of a five-month decline) and no pullback/oversold limit qualifies (countertrend - price 12.86 < SMA50 14.56 with MACD -0.38 < 0, and price < SMA200 17.78 with SMA50 < SMA200 and no momentum reclaim).

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

USANA Health Sciences, Inc. develops, manufactures, and sells nutritional, personal care, and skincare products across Asia Pacific, the Americas, and Europe. It operates through Core nutritional and Hiya Direct-To-Consumer segments, offering products like supplements, meal replacements, and skincare regimens. The company utilizes retail, subscription, and direct selling channels.

Fundamental

fair
Fundamental3
Mixed fundamentals

USANA shows strong cash reserves but faces declining core business and negative earnings projections.

Mixed, cash-backed but shrinking: zero debt and about $179M of cash cover roughly three-quarters of the market cap, free cash flow is positive and improving, and gross margin is 77%, while Core Nutritional customers and revenue keep declining, TTM GAAP earnings are negative (partly a $29.1M non-cash goodwill impairment), the effective tax rate is structurally high, and management guides FY2026 to a net loss. Deep-value optics against real operating erosion - an uncertain rather than a clean setup.

Sentiment

weak
Sentiment2
Negative sentiment

Recent earnings miss and guidance cut have led to a negative sentiment shift, with downgrades and estimate cuts.

Dominant catalyst is the announced Q3 2026 earnings miss and FY2026 guidance cut (2026-11-03: revenue $205.9M, -3.6% y/y / -5.6% constant currency, GAAP EPS $(0.30), adjusted EBITDA outlook lowered to $77M, shares down ~14.9% on the day), still being digested through a live stream of post-print estimate cuts and a Zacks downgrade to Strong Sell on 2026-11-06; the sentiment delta is determinately negative, from a baseline polarity_score of +0.20 (3 scored items, 2026-08-13 to 2026-10-12) to -0.31 in the scoring window (20 scored items, 2026-10-28 to 2026-11-11). A moderate red-flag cap applies for sharp 14-day sentiment deterioration with no offsetting bullish catalyst; no severe flag fired (no regulator-confirmed investigation, no going-concern, no auditor change or restatement, no distress-context financing).

Technical

weak
Technical2
Confirmed downtrend

The stock is in a downtrend, trading below all major moving averages with no signs of reversal.

Technical score 2: USNA is structurally broken on every timeframe. Price 12.86 (input snapshot; live quote 12.79) sits below SMA20 14.29, SMA50 14.56, SMA200 17.78, EMA9 13.71, EMA21 14.13 and today's VWAP 12.90, with the moving-average stack fully inverted (EMA9 < EMA21 < SMA50 < SMA200). MACD is negative and expanding (-0.38 line vs -0.22 signal, histogram -0.16) and ADX 16.11 shows no upside impulse. RSI 32.28 and Williams %R -96.84 are deeply oversold, but oversold inside a confirmed downtrend is a bounce candidate, not a reversal; the +12.92% bounce of 2026-11-04 (close 14.33) rolled straight back over within two sessions. No base, no reclaim, no momentum turn - bounce-only at best, hence 2 rather than 3.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.